ENRICH-AF

The following are some additional information with regards to ENRICH-AF:

• The purpose of this study is to determine whether edoxaban (60/30 mg daily) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) in high-risk atrial fibrillation (CHA2DS2-VASc score ≥2) patients with previous intracranial hemorrhage. 

• Edoxaban (60/30 mg daily) vs. non-anticoagulant medical therapy (no specific therapy for the prevention of blood clots or therapy with aspirin or another antiplatelet drug) 

Inclusion/Exclusion Criteria: